Rodman David Malcom's Form 4 filing
Mineralys Therapeutics, Inc. (MLYS) · filed Jan 13, 2026
- Accession no.
- 0001672659-26-000004
- Filed
- Jan 13, 2026
- Trade date
- Jan 9-12, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $277.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rodman David MalcomCIK 0001672659 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | Common Stock | MOption exerciseAcquired | +2,170 | $16.00 | +$34,720 | 63,974 | Direct | |
| Jan 9, 2026 | Common Stock | SSaleDisposed | −2,170 | $33.27 | −$72,195.9 | 61,804 | Direct | |
| Jan 12, 2026 | Common Stock | MOption exerciseAcquired | +6,348 | $1.08 | +$6,855.84 | 68,152 | Direct | |
| Jan 12, 2026 | Common Stock | SSaleDisposed | −6,348 | $32.32 | −$205,167.36 | 61,804 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | Common Stock | MOption exerciseDisposed | −2,170 | $0.00 | $0 | 28,218 | Direct | |
| Jan 12, 2026 | Common Stock | MOption exerciseDisposed | −6,348 | $0.00 | $0 | 38,092 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.